MK 8776

Drug Profile

MK 8776

Alternative Names: MK-8776; SCH 900776

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antineoplastics; Pyrazoles; Pyrimidines
  • Mechanism of Action Cell cycle inhibitors; Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Lymphoma; Solid tumours

Most Recent Events

  • 01 May 2013 Phase-II clinical trials in Acute myeloid leukaemia (combination therapy) in USA (IV)
  • 21 Feb 2012 Schering-Plough terminates a phase I trial in Leukaemia (combination therapy) in USA (NCT00907517)
  • 22 Jun 2011 Schering-Plough completes a phase I trial in Solid tumours and Lymphomas (combination therapy) in US (NCT00779584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top